FDA approves Keytruda for patients with metastatic NSCLC
5 October 2015 | By Victoria White
Keytruda is now the first and only anti-PD-1 ((programmed death receptor-1) therapy approved for both squamous and non-squamous metastatic NSCLC...
List view / Grid view
News
Teva acquires Mexican company Rimsa for $2.3b
2 October 2015 | By Victoria White
Through the Rimsa acquisition, Teva will become a leading pharmaceutical company in the second largest market in Latin America...
FDA accepts Sandoz’s BLA for biosimilar etanercept
2 October 2015 | By Victoria White
Sandoz is seeking approval for all indications included in the label of etanercept which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
Vernalis acquires US rights to Moxatag
2 October 2015 | By Victoria White
Moxatag is a penicillin-class antibacterial indicated for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes...
Santhera launches Raxone in its first EU market
2 October 2015 | By Victoria White
Raxone is also the first approved treatment for any mitochondrial disease, a therapeutic area which is in the focus of Santhera...
Merck and DNAtrix announce glioblastoma collaboration
2 October 2015 | By Victoria White
Merck and DNAtrix will evaluate the efficacy and safety of DNX-2401 in combination with Keytruda in a Phase 2 study...
Allergan completes $2.1 billion acquisition of Kythera
1 October 2015 | By Victoria White
The acquisition of Kythera adds Kybella, an injection for improvement in the appearance of moderate to severe submental fullness, to Allergan’s portfolio...
Genzyme opts into Alnylam’s ALN-AT3 haemophilia programme
1 October 2015 | By Victoria White
Genzyme has elected to opt into the programme for development and potential future commercialisation of ALN-AT3 in territories outside of North America and Western Europe...
FDA approves Opdivo + Yervoy in melanoma
1 October 2015 | By Victoria White
The announcement marks the first and only FDA approval of a Regimen of two immuno-oncology agents in cancer...
Secukinumab demonstrates efficacy in psoriatic arthritis
1 October 2015 | By Victoria White
Secukinumab is the first interleukin-17A inhibitor to demonstrate efficacy in a Phase III study in patients with active psoriatic arthritis...
Brodalumab studies demonstrate significant improvements in psoriasis
1 October 2015 | By Victoria White
Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signalling...
Martindale Pharma expands into Saudi Arabia
1 October 2015 | By Victoria White
The company has opened a Scientific Office in Saudi Arabia and has appointed Dr Fahad Al Showaier as Scientific Office Manager...
PTC submits EU application for Translarna for cystic fibrosis
30 September 2015 | By Victoria White
If approved, Translarna would be the first oral protein restoration treatment that targets the underlying cause of nonsense mutation cystic fibrosis...
Tenofovir linked to lower bone mineral content in newborns
30 September 2015 | By Victoria White
Pregnant women who received the anti-HIV drug in their third trimester gave birth to babies whose bone mineral content was 12% lower than that of infants who were not exposed to the drug...
Coulter Partners announces expansion into Germany with new offices in Frankfurt and Berlin.
30 September 2015 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce the appointments of Anne-Monika Dürk as Executive Vice President, Thomas Pilz as Research Associate and Ronja Lindenberg as Executive Assistant in their new Frankfurt offices....
